Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Inflammation Parameters in Philadelphia Negative Chronic Myeloproliferative Neoplasia Patients

  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Chronic myeloproliferative diseases are clonal stem cell diseases which occur as a result of uncontrollable growth and reproduction of hematopoietic stem cells, which are the myeloid series source in bone marrow. Recent studies have suggested that chronic inflammation can be a triggering factor in the clonal change in chronic myeloproliferative neoplasia (CMPN). In our study, we evaluated the existence of a chronic inflammation process in our Philadelphia negative (Ph-)CMPN patients using inflammation parameters in combination with demographic, laboratory and clinical characteristics of the patients. Materials and Methods: Demographic characteristics, clinical and laboratorial data, and thrombosis histories of 99 Ph-CMPN patients, who were diagnosed at our outpatient clinic of hematology in accordance with WHO 2008 criteria, were analyzed retrospectively,with 80 healthy individuals of matching gender and age included as controls. Complete blood counts, sedimentation, C reactive protein (CRP), JAK V617F gene mutations, abdomen ultrasound images and previous thrombosis histories of these patients were retrospectively analyzed. Results: Ph-CMPN and healthy control groups included 99 and 80 cases, respectively. PV, ET and MF diagnoses of patients were 43 (%43.4), 44 (44.4%) and 12 (12.1%), respectively. JAK V617F gene mutation was found to be positive in 64 (71.1%) of all cases and in 27(65.8%), 32 (82%), 5 (50%) of the cases in PV, ET and PMF groups, respectively. Thrombosis was determined as 12 (12%) in the entire group, 12.5% in the JAK V617F negative and 15.3% in the positive patients, with no statistical significance (p=0.758). No significant difference was observed between patients with and without previous thrombosis history in respect to hemogram parameters, sedimentation and CRP (p>0.05), neutrophil to lymphocyte ratio (NLR), erythrocyte distribution width (RDW), mean platelet volume (MPV) and sedimentation levels of the patient.

Keywords

References

  1. Aktas G, Alcelik A, Tekce BK, et al (2014). Red cell distribution width and mean platelet volume in patients with irritable bowel syndrome. Pzr Gastroenterol, 9, 160-3.
  2. Barbui T, Carobbio A, Finazzi G, et al (2011). Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Hematologica, 96, 315-8. https://doi.org/10.3324/haematol.2010.031070
  3. Barbui T, Carobbio A, Rambaldi A, et al (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood, 114, 759-63.
  4. Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al (2011). Mean platelet volume: a link between thrombosis and inflammation. Curr Pharm Des, 17, 47-58. https://doi.org/10.2174/138161211795049804
  5. Gunay E, Sarinc Ulasli S, Akar O, et al (2014). Neutrophil-tolymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation, 37, 374-80. https://doi.org/10.1007/s10753-013-9749-1
  6. Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM (2013). Association between C-reactive protein and risk of cancer: a metaanalysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8. https://doi.org/10.7314/APJCP.2013.14.1.243
  7. Hasselbalch HC.(2013). Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development. Leuk Reus, 37, 214-20. https://doi.org/10.1016/j.leukres.2012.10.020
  8. Hasselbalch HC. et al (2012). Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer. Blood, 119, 3219-25. https://doi.org/10.1182/blood-2011-11-394775
  9. Karaman H, Karaman A, Erden A, et al (2013) Relationship between colonic polyp type and the neutrophil/ lymphocyte ratio as a biomarker. Asian Pac J Cancer Prev, 14, 3159-61. https://doi.org/10.7314/APJCP.2013.14.5.3159
  10. Kilincalp S, Ekiz F, Basar O, et al (2014). Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets, 25, 592-4. https://doi.org/10.3109/09537104.2013.783689
  11. Kitazawa T, Yoshino Y, Tatsuno K, et al (2013). Changes in the mean platelet volume levels after bloodstream infection have prognostic value. Intern Med, 52, 1487-93. https://doi.org/10.2169/internalmedicine.52.9555
  12. Kremyanskaya M, Najfeld V, Mascarenhas J, et al (2013). Essential Thrombocythemia Ronald Hoffman, MD, Edward J. Benz eds: Hematology, 6th Edition Basic Principles and Practice, chapter 68, 1037-8.
  13. Kremyanskaya M, Najfeld V, Mascarenhas J, et al (2013). The polycythemias Ronald Hoffman, MD, Edward J. Benz eds: Hematology, 6th Edition Basic Principles and Practice, chapter, 67, 1014-5.
  14. Landolfi R, Di Gennaro L (2011). Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica, 96, 183-6. https://doi.org/10.3324/haematol.2010.038299
  15. Makay B, Gucenmez OA, Duman M, et al (2014). The relationship of neutrophil-to-lymphocyte ratio with gastrointestinal bleeding in Henoch-Schonlein purpura. Rheumatol Int, 34, 1323-7 https://doi.org/10.1007/s00296-014-2986-2
  16. Payzin KB, Savasoglu K, Alacacioglu I, et al (2014). JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk, 14, 525-33. https://doi.org/10.1016/j.clml.2014.02.013
  17. Sakalli H, Kal O,(2013). Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever. Clin Rheumatol, 32, 1185-90. https://doi.org/10.1007/s10067-013-2257-8
  18. Takaya Y1, Seki R, Kanajii T, et al (2014). Association between Thromboembolic Events and the JAK2 V617F Mutation in Myeloproliferative Neoplasms. Kurume Med J, 60, 89-97. https://doi.org/10.2739/kurumemedj.MS63001
  19. Tefferi A. (2012). Polycythemia vera and essential thrombocythemia: update on diagnosis, risk stratification, and management. Am J Hematol, 87, 285-93.
  20. Unal D, Eroglu C, Kurtul N, Oguz A, et al (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J CancerPrev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  21. Vannucchi AM, Antonioli E, Guglielmelli P, et al (2008). Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia, 22, 1299-307. https://doi.org/10.1038/leu.2008.113
  22. Vannucchi AM, Guglielmelli P.(2013). JAK2 mutation-related disease and thrombosis. Semin Thromb Hemost, 39, 496-506. https://doi.org/10.1055/s-0033-1343890
  23. Yu Q, Yu XF, Zhang SD, et al (2013). Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 5735-40. https://doi.org/10.7314/APJCP.2013.14.10.5735

Cited by

  1. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis vol.107, pp.2, 2018, https://doi.org/10.1007/s12185-017-2348-4